Advice
in the absence of a submission from the holder of the marketing authorisation:
daratumumab (Darzalex®) is not recommended for use within NHSScotland.
Indication under review: In combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice612KB (PDF)
Medicine details
- Medicine name:
- daratumumab (Darzalex)
- SMC ID:
- SMC2269
- Indication:
In combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 February 2020